News

Video

Data From the AtTEnd: Study: Atezolizumab Plus Carboplatin and Paclitaxel for Treatment of Advanced Endometrial Cancer

Author(s):

Floor J. Backes, MD,Matthew A. Powell, MD, Washington University in St. Louis

Drs Powell and Backes discuss additional immunotherapy trial results from ESMO 2023 including AtTEnd and DUO-E, noting differences across trials likely due to patient population composition rather than drug differences, and need for caution with PARP inhibitor maintenance.

Related Videos
Kathleen N. Moore, MD, MS
Matthew Powell, MD
Alberto Montero, MD, MBA, CPHQ
Kathleen N. Moore, MD, MS
Matthew Powell, MD
Laura J. Chambers, DO
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Maurie Markman, MD
Salman R. Punekar, MD
Related Content
Katsyarina – stock.adobe.com
December 3rd 2024

NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer

Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD
January 11th 2024

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

Alberto Montero, MD, MBA, CPHQ, clinical director, Breast Cancer Medical Oncology Program, Diana Hyland Chair for Breast Cancer, University Hospitals Seidman Cancer Center
November 20th 2024

STK-478 May Be an Effective, Tolerable Treatment Alternative in PIK3CA-Mutant Breast and Gynecologic Cancers

R. Wendel Naumann, MD
October 26th 2023

Naumann Discusses Notable Research Efforts in Endometrial Cancer

BT7480 in Nectin-4+, CD137+ Tumors | Image Credit: © Katsyarina - stock.adobe.com
November 7th 2024

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors

Angeles Alvarez Secord, MD, MHSc, of Duke Cancer Institute
November 5th 2024

Gynecologic Cancer Paradigm Sees Huge Gains With FDA-Approved Regimens